An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell Lymphoma

This study is testing a new type of CAR-T cell therapy — where immune cells are taken from your body, engineered in a lab to target cancer, and then put back — for people with aggressive B-cell lymphoma that has come back or stopped responding to treatment. This therapy targets two proteins on cancer cells (CD19 and CD20) at the same time. **You may be eligible if...** - You are 18 or older - You have relapsed or refractory aggressive B-cell lymphoma - You have already received at least two prior treatments (including chemotherapy and rituximab) without lasting benefit - Your lymphoma cells are confirmed to express CD19 and/or CD20 - Your organs are functioning well enough for treatment **You may NOT be eligible if...** - Your lymphoma is only in the brain (primary CNS lymphoma) - You have an active infection including HIV, hepatitis B or C, CMV, EBV, or syphilis - You have had major surgery in the past 4 weeks - You are on high-dose steroids or immune-suppressing medications - You are pregnant or breastfeeding - You have another active cancer (within 5 years, with some exceptions) Talk to your doctor to see if this trial is right for you.